首页分子通1-[5-tert-butyl-2-(2-methoxyethyl)-2H-pyrazol-3-yl]-3-((1S,4R)-4-{3-[4-(2-dimethylaminoethoxy)-piperidin-1-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydronaphthalen-1-yl)urea hydrogen chloride salt
1-[5-tert-butyl-2-(2-methoxyethyl)-2H-pyrazol-3-yl]-3-((1S,4R)-4-{3-[4-(2-dimethylaminoethoxy)-piperidin-1-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydronaphthalen-1-yl)urea hydrogen chloride salt
1-[5-tert-butyl-2-(2-methoxyethyl)-2H-pyrazol-3-yl]-3-((1S,4R)-4-{3-[4-(2-dimethylaminoethoxy)-piperidin-1-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydronaphthalen-1-yl)urea hydrogen chloride salt
Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
[EN] KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES
申请人:CHIESI FARMA SPA
公开号:WO2014195400A1
公开(公告)日:2014-12-11
This invention relates to compounds and compositions that are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.